Gamma Diagnostics

Executive Summary

Gamma Diagnostics is a San Diego-based private company specializing in Gamma Prime Fibrinogen (GPF), a novel biomarker for predicting clotting and inflammation in cardiovascular disease and other conditions such as COVID-19. Founded in 2009, the company commercializes the GammaCoeur test kit, which enables accurate detection of clotting risk and improved treatment decisions. With a focus on an underserved biomarker space, Gamma Diagnostics addresses a critical need in thrombosis and inflammation management, particularly post-pandemic where clotting complications remain a concern. The company's technology leverages GPF's role as an early indicator of thrombotic events, potentially offering a competitive edge over traditional coagulation tests. While financial details and stage remain undisclosed, the company's long-standing presence and specialized focus suggest a niche but potentially high-impact position in the diagnostics market.

Upcoming Catalysts (preview)

• H2 2027FDA 510(k) Clearance for GammaCoeur Test40% success
• Q4 2026Publication of Clinical Validation Study in COVID-19 Patients60% success
• TBDStrategic Partnership with Major Diagnostics Distributor30% success